June 1, 2022
TPX-100: OrthoTrophix Presents the Latest Clinical Data at BIO 2022
April 8, 2022
TPX-100: OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis
September 21, 2021
TPX-100: OrthoTrophix Published a New Research Article Demonstrating Disease Modification in Knee Osteoarthritis
Welcome
OrthoTrophix is a biopharmaceutical company focused on development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone and cartilage. The primary focus of OrthoTrophix is development of a first-in-class disease modifying osteoarthritis drug (DMOAD). The company’s leading therapeutic compound,